PL2558105T3 - Metylowany bardoksolon do leczenia otyłości - Google Patents

Metylowany bardoksolon do leczenia otyłości

Info

Publication number
PL2558105T3
PL2558105T3 PL11715645T PL11715645T PL2558105T3 PL 2558105 T3 PL2558105 T3 PL 2558105T3 PL 11715645 T PL11715645 T PL 11715645T PL 11715645 T PL11715645 T PL 11715645T PL 2558105 T3 PL2558105 T3 PL 2558105T3
Authority
PL
Poland
Prior art keywords
obesity
treatment
bardoxolone methyl
bardoxolone
methyl
Prior art date
Application number
PL11715645T
Other languages
English (en)
Inventor
Colin J. Meyer
Warren Huff
Original Assignee
Reata Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44259866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2558105(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Reata Pharmaceuticals, Inc. filed Critical Reata Pharmaceuticals, Inc.
Publication of PL2558105T3 publication Critical patent/PL2558105T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
PL11715645T 2010-04-12 2011-04-12 Metylowany bardoksolon do leczenia otyłości PL2558105T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32327610P 2010-04-12 2010-04-12
US38909010P 2010-10-01 2010-10-01
PCT/US2011/032156 WO2011130302A2 (en) 2010-04-12 2011-04-12 Method of treating obesity using antioxidant inflammation modulators
EP11715645.5A EP2558105B1 (en) 2010-04-12 2011-04-12 Bardoxolone methyl for the treatment of obesity

Publications (1)

Publication Number Publication Date
PL2558105T3 true PL2558105T3 (pl) 2020-04-30

Family

ID=44259866

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11715645T PL2558105T3 (pl) 2010-04-12 2011-04-12 Metylowany bardoksolon do leczenia otyłości

Country Status (29)

Country Link
US (2) US10105372B2 (pl)
EP (1) EP2558105B1 (pl)
JP (1) JP5990160B2 (pl)
KR (1) KR101819699B1 (pl)
CN (1) CN102939089B (pl)
AU (1) AU2011240690C1 (pl)
BR (1) BR112012026112B1 (pl)
CA (1) CA2795320C (pl)
CL (1) CL2012002859A1 (pl)
CY (1) CY1122480T1 (pl)
DK (1) DK2558105T3 (pl)
EA (1) EA026567B1 (pl)
ES (1) ES2768204T3 (pl)
HR (1) HRP20192291T1 (pl)
HU (1) HUE047994T2 (pl)
IL (1) IL222273B (pl)
LT (1) LT2558105T (pl)
ME (1) ME03713B (pl)
MX (1) MX357596B (pl)
MY (1) MY163031A (pl)
NZ (1) NZ602826A (pl)
PL (1) PL2558105T3 (pl)
PT (1) PT2558105T (pl)
RS (1) RS59850B1 (pl)
SG (2) SG10201808661XA (pl)
SI (1) SI2558105T1 (pl)
TW (1) TWI558724B (pl)
WO (1) WO2011130302A2 (pl)
ZA (1) ZA201207518B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
MX356760B (es) 2008-01-11 2018-06-12 Dartmouth College Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad.
CN102066397B (zh) 2008-04-18 2013-09-11 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
US7915402B2 (en) 2008-04-18 2011-03-29 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
WO2009129548A1 (en) 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
AU2009237579C1 (en) 2008-04-18 2016-05-12 Reata Pharmaceuticals Holdings, LLC Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
PL2558105T3 (pl) * 2010-04-12 2020-04-30 Reata Pharmaceuticals, Inc. Metylowany bardoksolon do leczenia otyłości
EA025568B1 (ru) 2010-12-17 2017-01-30 Рита Фармасьютикалз, Инк. Пиразолильные и пиримидинильные трициклические еноны в качестве антиоксидантных модуляторов воспаления
EA026847B1 (ru) 2011-03-11 2017-05-31 Рита Фармасьютикалз, Инк. C4-монометилтритерпеноидные производные и способы их применения
KR101174701B1 (ko) * 2011-12-29 2012-08-17 서울대학교산학협력단 진저레논 에이를 포함하는 비만 예방용 식품 조성물, 비만 치료용 약학조성물 및 비만 치료용 동물용 의약품
PE20150160A1 (es) 2012-04-27 2015-02-19 Reata Pharmaceuticals Inc Derivados de 2,2-difluoropropionamida de bardoxolona metilo, formas polimorficas y metodos de uso de los mismos
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
WO2014040052A2 (en) 2012-09-10 2014-03-13 Abbvie Inc. Glycyrrhetinic acid derivatives and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
UY35023A (es) 2012-09-10 2014-03-31 Reata Pharmaceuticals Inc Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
RS58010B1 (sr) 2012-09-27 2019-02-28 Childrens Medical Ct Corp Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu
TW201514192A (zh) 2013-03-19 2015-04-16 Daiichi Sankyo Co Ltd 萜類衍生物
TW201936625A (zh) 2013-04-24 2019-09-16 美商艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
EA201690456A1 (ru) * 2013-08-23 2016-06-30 Рита Фармасьютикалз, Инк. Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов
WO2015112792A1 (en) 2014-01-24 2015-07-30 Abbvie Inc. Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
AU2015256178B2 (en) 2014-05-05 2020-02-27 The Board Of Regents Of The University Of Texas System Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
ES2770772T3 (es) 2014-09-10 2020-07-03 Daiichi Sankyo Co Ltd Composición farmacéutica de liberación sostenida para el tratamiento y prevención de enfermedades oculares
KR20170117092A (ko) 2015-02-12 2017-10-20 리아타 파마슈티컬즈, 아이엔씨. 항산화 염증 조절제로서의 이미다졸릴 트리사이클릭 에논
CN105017374B (zh) * 2015-07-20 2017-03-01 山西大学 一种齐墩果酸内酯类衍生物及其制备方法和应用
US20170056373A1 (en) * 2015-09-01 2017-03-02 Syracuse University Ghrelin o-acyltransferase inhibitors
CA2998681C (en) 2015-09-23 2024-02-06 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
US11207333B2 (en) 2016-09-08 2021-12-28 Regenera Pharma Ltd. Compositions comprising triterpenoids and uses thereof for treating optic neuropathy
BR112019009256A2 (pt) 2016-11-08 2019-07-16 Reata Pharmaceuticals Inc métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
CN116018136A (zh) * 2020-04-29 2023-04-25 百爱及生物医药公司 用于治疗衰老相关病症的缺氧诱导因子脯氨酰羟化酶抑制剂

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
NZ191586A (en) 1978-10-10 1981-10-19 Sterling Drug Inc Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
PT1178952E (pt) 1999-05-14 2007-12-04 Univ California Novos moduladores da interleucina-1 e do factor alfa de necrose tumoral, síntese dos referidos moduladores e métodos de utilização dos referidos moduladores
US6890946B2 (en) 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
WO2002003996A1 (en) 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
EP1322661A1 (en) 2000-09-29 2003-07-02 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
US6878751B1 (en) 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
CA2430454A1 (en) 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
NZ528394A (en) * 2001-03-23 2005-06-24 Shire Biochem Inc Pharmaceutical combinations for the treatment of cancer comprising dioxolane analogues and nuceloside analogues and/or chemotherapeutic agents
AU2002308701A1 (en) 2001-05-14 2002-11-25 University Of Maryland, Baltimore Novel alanine transaminase enzyme and methods of use
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
AU2003303128A1 (en) 2002-05-13 2004-08-13 Trustees Of Dartmouth College Inhibitors and methods of use thereof
EP1457206A1 (en) * 2003-03-13 2004-09-15 Fournier Laboratories Ireland Limited Combined use of a fibrate and orlistat for the treatment of obesity
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
CA2523408A1 (en) 2003-05-09 2004-11-18 Novo Nordisk A\S Peptides for use in treating obesity
RU2005133970A (ru) * 2003-05-09 2007-06-20 Ново Нордиск А/С (DK) Пептиды, применяемые для лечения ожирения
WO2004105517A1 (en) 2003-05-27 2004-12-09 Dsm Ip Assets B.V. Novel nutraceutical compositions and use thereof
WO2005042002A2 (en) 2003-10-30 2005-05-12 Entelos, Inc. Treatment of rhematoid arthritis with flip antagonists
US8288439B2 (en) 2003-11-04 2012-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the inhibition of HIV-1 replication
ZA200604862B (en) 2003-12-22 2007-10-31 Alcon Inc Agents for treatment of glaucomatous retinopathy and optic neuropathy
JP2005314381A (ja) 2004-03-30 2005-11-10 Anges Mg Inc 増殖性腎疾患の予防・治療・改善剤
WO2005113761A2 (en) 2004-04-19 2005-12-01 University Of Maryland, Baltimore Novel alanine transaminase enzymes and methods of use
US7772195B2 (en) 2004-07-29 2010-08-10 Board Of Trustees Of Michigan State University Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
EP1811840B1 (en) 2004-09-07 2016-04-13 May Sung Mak Anti-tumor compounds with angeloyl groups
CA2614110A1 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
US20070249561A1 (en) 2006-04-25 2007-10-25 Taylor Bradley K Pharmacological method for treatment of neuropathic pain
CA2653726C (en) 2006-06-27 2015-05-12 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
JP2008110962A (ja) 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
WO2008016095A1 (fr) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
WO2008064132A2 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US7714012B2 (en) 2006-11-17 2010-05-11 Trustees Of Dartmouth University Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
WO2008111497A1 (ja) 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
WO2009023845A2 (en) 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
US9012439B2 (en) 2007-10-29 2015-04-21 University Of Rochester Use of electrophilic compounds for inducing platelet production or maintaining platelet function
MX356760B (es) * 2008-01-11 2018-06-12 Dartmouth College Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad.
US8071632B2 (en) * 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CN102066397B (zh) 2008-04-18 2013-09-11 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
AU2009237579C1 (en) 2008-04-18 2016-05-12 Reata Pharmaceuticals Holdings, LLC Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
WO2009129548A1 (en) 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
US7915402B2 (en) 2008-04-18 2011-03-29 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
PL3254675T3 (pl) 2009-02-13 2019-09-30 Reata Pharmaceuticals, Inc. Kompozycje doustne o opóźnionym uwalnianiu, zawierające amorficzny cddo-me
PL2558105T3 (pl) * 2010-04-12 2020-04-30 Reata Pharmaceuticals, Inc. Metylowany bardoksolon do leczenia otyłości
US8618125B2 (en) 2011-01-14 2013-12-31 Heptiva LLC Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance
CN102887936A (zh) 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
CN102875634B (zh) 2012-10-24 2014-08-20 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型

Also Published As

Publication number Publication date
JP5990160B2 (ja) 2016-09-07
CL2012002859A1 (es) 2013-08-02
SG10201808661XA (en) 2018-11-29
CN102939089A (zh) 2013-02-20
TWI558724B (zh) 2016-11-21
AU2011240690A1 (en) 2012-10-25
ZA201207518B (en) 2017-08-30
EP2558105A2 (en) 2013-02-20
WO2011130302A2 (en) 2011-10-20
CY1122480T1 (el) 2021-01-27
MX357596B (es) 2018-07-16
AU2011240690B2 (en) 2014-06-19
SI2558105T1 (sl) 2020-02-28
NZ602826A (en) 2014-11-28
US10105372B2 (en) 2018-10-23
EP2558105B1 (en) 2019-11-20
LT2558105T (lt) 2020-02-10
MY163031A (en) 2017-07-31
US11911395B2 (en) 2024-02-27
MX2012011892A (es) 2012-11-30
DK2558105T3 (da) 2020-01-27
PT2558105T (pt) 2020-01-30
JP2013523888A (ja) 2013-06-17
US20110281955A1 (en) 2011-11-17
ME03713B (me) 2021-01-20
US20190076443A1 (en) 2019-03-14
KR20130096635A (ko) 2013-08-30
BR112012026112A2 (pt) 2016-06-28
HRP20192291T1 (hr) 2020-03-20
IL222273B (en) 2019-03-31
IL222273A0 (en) 2012-12-31
WO2011130302A3 (en) 2012-01-05
HUE047994T2 (hu) 2020-05-28
RS59850B1 (sr) 2020-02-28
KR101819699B1 (ko) 2018-01-17
EA201291031A1 (ru) 2013-04-30
CA2795320A1 (en) 2011-10-20
AU2011240690C1 (en) 2014-11-06
CA2795320C (en) 2019-01-22
SG184830A1 (en) 2012-11-29
ES2768204T3 (es) 2020-06-22
TW201139458A (en) 2011-11-16
EA026567B1 (ru) 2017-04-28
CN102939089B (zh) 2018-04-10
BR112012026112B1 (pt) 2020-03-17

Similar Documents

Publication Publication Date Title
PL2558105T3 (pl) Metylowany bardoksolon do leczenia otyłości
ZA201304280B (en) Treatment of jak2-mediated conditions
PL2652193T3 (pl) Obróbka
PT2621569T (pt) Dispositivo de tratamento
EP2654745A4 (en) COMPOSITION FOR TREATING SKIN CONDITIONS OF THE SKIN
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
EP2389388A4 (en) TREATMENT OF OBESITY
EP2621498A4 (en) COMBINED TREATMENT OF DERMATOLOGICAL CONDITIONS
EP2543660A4 (en) PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST DIABETES OR ADIPOSITAS
HRP20181879T1 (hr) Spojevi za liječenje pretilosti i postupci za njihovu upotrebu
EP2415408A4 (en) TREATMENT DEVICE
EP2522360A4 (en) VACCINE FOR TAUTOPATHY TREATMENT
EP2536436A4 (en) ANTIMIR-451 FOR THE TREATMENT OF POLYCYTHEMICS
GB201013573D0 (en) Treatment
GB201018622D0 (en) Treatment of liquids
EP2554165A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY
GB201015970D0 (en) Pipe splint
PL2608685T3 (pl) Urządzenie do obróbki tytoniu
PL2566419T3 (pl) Orteza
TWM402081U (en) Bathtub
GB201014097D0 (en) Treatment
GB2483219B (en) Surface Treatment
GB201007519D0 (en) Means for inhibiting the expression of rragb
GB201021319D0 (en) Treatment
GB201009806D0 (en) Sewage treatment